BIT
Pharmaceuticals, Biotechnology & Life Sciences
Biotron
- Short interest
- 0.03%
- +0.01 pp 30d
- as of 20 Nov 2025
- Reported shorts
- 421.6K
- Shares on issue
- 1.526B
Biotron (BIT) company profile
Profile, insiders and operations
Company
AI-generated research profile of Biotron
Pharmaceuticals
Biotechnology
Antiviral Therapies
Clinical Trials
ASX
Biotron Limited is an Australian biotechnology company focused on developing and commercializing antiviral therapies. Their lead compound, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C, targeting viroporin proteins crucial for viral pathogenicity. The company leverages a proprietary screening platform and has a library of compounds with potential against various viral diseases, including SARS-CoV-2.
Director trades
8 trades recorded
BIT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required